Table 2.
KRAS/TP53 Co-Mutation Patients (N = 20)
| ID | KRAS Mutation | TP53 Mutation | ||||
|---|---|---|---|---|---|---|
| Mutation Site | Mutation Subtypes | Mutation Frequency | Mutation Site | Mutation Subtypes | Mutation Frequency | |
| P01 | Exon 2 | p.G12V | 19.48% | Exon 10 | Nonsense mutations | 27.93% |
| P02 | Exon 2 | p.G12D | 23.83% | Exon 7 | Missense mutation | 23.46% |
| P03 | Exon 2 | p.G12D | 15.91% | Exon 7 | Missense mutation | 20.87% |
| P04 | Exon 2 | p.G12D | 17.49% | Exon 5 | Missense mutation | 5.94% |
| P05 | Exon 2 | p.G12V | 26.00% | Exon 5 | Missense mutation | 33.10% |
| P06 | Exon 4 | p.K117N | 24.10% | Exon 8 | Missense mutation | 10.50% |
| P07 | Exon 2 | p.G12V | 5.25% | Exon 4 | Frameshift mutation | 28.10% |
| P08 | Exon 2 | p.G12V | 18.50% | Exon 8 | Missense mutation | 26.90% |
| P09 | Exon 2 | p.G12V | 39.27% | Exon 2 | Missense mutation | 21.75% |
| P10 | Exon 2 | p.G12D | 34.84% | Exon 8 | Nonsense mutations | 51.33% |
| P11 | Exon 2 | p.G12V | 5.75% | Exon 9 | Frameshift mutation | 3.97% |
| P12 | Exon 2 | p.G12D | 7.63% | Exon 5 | Missense mutation | 12.23% |
| P13 | Exon 2 | p.G12V | 4.95% | Exon 7 | Missense mutation | 4.72% |
| P14 | Exon 2 | p.G12C | 3.71% | Exon 3 | Frameshift mutation | 7.64% |
| P15 | Exon 2 | p.G12D | 14.78% | Exon 6 | Missense mutation | 8.63% |
| P16 | Exon 2 | p.G12V | 5.52% | Exon 6 | Frameshift mutation | 7.28% |
| P17 | Exon 2 | p.G12D | 7.30% | Exon 6 | Nonsense mutations | 6.50% |
| P18 | Exon 2 | p.G12V | 18.90% | Exon 5 | Missense mutation | 27.20% |
| P19 | Exon 2 | p.G12V | 17.80% | Exon 5 | Frameshift mutation | 2.60% |
| P20 | Exon 2 | p.G12D | 31.50% | Exon 5 | Missense mutation | 73.20% |